Latest news and press releases about Ainos, Inc. (AIMD): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications.
Price
| Price | $1.38 |
| Market Cap | $10M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.82 |
| EV / EBITDA | -2.60 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -217.50% |
| Return on Invested Capital | -80.51% |
| Return on Assets | -73.89% |
| Gross Margin | -34987.54% |
| Operating Margin | -101210.17% |
| Net Margin | -106283.32% |
Related companies: ADTX · ANL · ATHA · BLRX · DARE · FBLG · GOVX
Explore sector: Healthcare · Biotechnology
More sections of AIMD: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks